Navigation Links
Pediatric Asthma Programs Featuring PARI Pharma's eFlow Acquired by AstraZeneca

MONTEREY, Calif., Sept. 24 /PRNewswire/ -- Today, the rights to Verus Pharmaceuticals' pediatric asthma development programs that utilize PARI's eFlow electronic nebulizer for aerosol delivery were acquired by AstraZeneca. Following Gilead Sciences' acquisition of Corus Pharma in August 2006, this is the second major pharmaceutical acquisition where a licensed eFlow is featured prominently in the development pipeline.

Included in the AstraZeneca acquisition are the North American rights to a Captisol(R) enabled budesonide solution (controller medication), a proprietary short-acting beta-agonist solution (rescue medication), a customized version of eFlow(R) (novel aerosol delivery device) for use with both products, and other intellectual property and related assets from Verus.

This is the second acquisition by a large pharmaceutical company where purchases have included the licensing of PARI's eFlow in the development program. In August 2006, Gilead Sciences acquired Corus Pharma for $365 million. In December 2006, Gilead Sciences released positive preliminary results of their Phase III trial on AIR-CF2, a potential treatment for cystic fibrosis patients that have pulmonary Pseudomonas aeruginosa. These positive preliminary results were the first Phase III clinical trial results highlighting the optimization of drug to device and device to drug with PARI's eFlow, an advanced electronic nebulizer.

About eFlow

eFlow uses a vibrating, perforated membrane that enables extremely efficient aerosolization of liquid medications. Compared to other nebulizer systems, eFlow can produce aerosols with a very high density of active drug, a precisely defined droplet size, and a high proportion of respirable droplets delivered in the shortest possible amount of time. Combined with its silent mode of operation, small size (it fits in the palm of your hand), light weight, and battery use, eFlow helps reduce the burden of taking daily-inhaled treatments.

Due to its efficiency, eFlow is licensed to pharmaceutical companies during drug development and for later commercialization so that drug and device are optimized together for the final product. This customization is currently being utilized in the development of new and improved treatments for cystic fibrosis, asthma, and chronic obstructive pulmonary disease (COPD).

About PARI Pharma

PARI Pharma develops aerosol delivery devices and inhaled therapies. Based on PARI's 100-year history working with aerosols, PARI Pharma specializes in treatments for pulmonary and nasal administration optimized to advanced delivery platforms, such as eFlow.

Focusing on comprehensive inhalation therapy development, including optimized nebulizer formulations, analytics, and aerosol characterization, PARI Pharma has several clinical development programs ongoing, either partnered or proprietary. PARI Pharma, a PARI Medical Holding company, is located in Munich, Germany, with a major presence in the United States. Online at

Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. High-throughput gene expression analysis to screen for anti-asthma drugs
2. Bio-Plex Cytokine Immunoassays and ELISA: Comparison of Two Methodologies in Testing Samples From Asthmatic and Healthy Children, Rev A
3. Are guest worker programs causing backlash amid IT downsizing?
4. FDA programs encourage and expedite drug development and approval
5. SecurePipe acquires mailMax programs
6. British come to Madison; UW starts stem-cell programs
7. Stem-cell study grows too big for one department; UW builds collaborative programs
8. Inacom targets diversity programs as Milwaukee expansion drives growth
9. Interview: New commerce secretary wants to keep momentum on jobs and business programs
10. Experts share advice for Wisconsin entrepreneur programs
11. An analysis of Wisconsins new venture capital and early stage finance programs
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software as ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and video ... trial team. , Using the CONSULT module, patients and physicians can schedule a face ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader ... “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, ... providing practical tips, tools, and strategies for clinical researchers. , “The landscape of ...
Breaking Biology Technology:
(Date:6/15/2016)... 15, 2016 Transparency Market ... Recognition Market by Application Market - Global Industry Analysis Size ... to the report, the  global gesture recognition market ... and is estimated to grow at a CAGR ... 2024.  Increasing application of gesture recognition ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
Breaking Biology News(10 mins):